Streetbeat News

Analyst Ratings

CLX

Over the past three months, 12 analysts have evaluated Clorox (NYSE:CLX), showing a range of sentiments from indifferent to somewhat bearish. The average 12-month price target has decreased by 4.23% to $147.92. Recent analyst actions include several downgrades and lowered price targets, reflecting concerns over Clorox's financial performance, including declining revenue, negative net margin, and high debt levels.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 7:00 pm

KMX

Analysts' ratings for CarMax (NYSE:KMX) over the last quarter show a mix of bullish and bearish sentiments. The average 12-month price target is $80.59, a slight decrease from the previous $82.62. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 7:00 pm

FDX

FedEx Corporation (NYSE:FDX) is set to announce its Q4 financial results on June 25. Analysts expect revenue of $22.06 billion and EPS of $5.37. The company has missed revenue estimates for eight consecutive quarters but has beaten EPS estimates in seven of the last ten quarters. Key items to watch include job cuts, cost-saving measures, and a $5 billion share buyback plan.

Portfolio Pulse from Chris Katje

June 24, 2024 | 7:00 pm

CRWD

Investor Business Daily's SwingTrader has added CrowdStrike (CRWD) to its portfolio, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:50 pm

NVO

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) released promising Phase 1 data on garetosmab and trevogrumab, showing significant improvements in body composition. Goldman Sachs maintains a Buy rating with a $1,180 price target. Regeneron is also conducting a Phase 2 study with Novo Nordisk's (NYSE:NVO) semaglutide. REGN shares are up 1.29%.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 6:36 pm

ALNY

Needham analyst Joseph Stringer maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $200 to $275.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:33 pm

TLS

Needham analyst Alex Henderson has reiterated a Hold rating on Telos (NASDAQ:TLS).

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:31 pm

NTLA

Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:30 pm

TSLA

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Tesla (NASDAQ:TSLA) and maintained a $230 price target.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:28 pm

BYND

Beyond Meat, Inc. (NASDAQ:BYND) shares are trading higher on above-average volume following the announcement of its fourth generation Beyond Sausage. The company is also cutting its 2024 budget by $70 million. Despite these developments, the stock has fallen 25% year-to-date and faces a potential short-squeeze with 38.88% of shares sold short. Analysts have a mixed outlook with no positive ratings and an average 12-month price target of $6.3.

Portfolio Pulse from Erica Kollmann

June 24, 2024 | 6:27 pm